Pablo Román-García

Pablo Román-García

Auto-generated profile, based on publicly available information

Pablo Román-García

Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación Nefrológica, REDinREN del ISCIII, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Science
Verified
Journal Article
Closed access
PDF file
JTJose M. C. Tubio
Jose M. C. Tubio
YLYilong Li
Yilong Li
YJYoung Seok Ju
Young Seok Ju
IMInigo Martincorena
Inigo Martincorena
SCSusanna L. Cooke
Susanna L. Cooke
PCPeter J. Campbell
Peter J. Campbell
Introduction: The human genome is peppered with mobile repetitive elements called long interspersed nuclear element–1 (L1) retrotransposons. Propagating through RNA and cDNA intermediates, these molecular parasites copy and insert themselves throughout the genome, with potentially disruptive effects on neighboring genes or regulatory sequences. In the germ line, unique sequence downstream of L1 elements can also be retrotransposed if transcription continues beyond the repeat, a process known as 3′ transduction. There has been growing interest in retrotransposition and 3′ transduction as a possible source of somatic mutations during tumorigenesis. Rationale: To explore whether 3′ transductions are frequent in cancer, we developed a bioinformatic algorithm for identifying somatically acquired retrotranspositions in cancer genomes. We applied our algorithm to 290 cancer samples from 244 patients across 12 tumor types. The unique downstream sequence mobilized with 3′ transductions effectively fingerprints the L1 source element, providing insights into the activity of individual L1 loci across the genome. Results: Across the 290 samples, we identified 2756 somatic L1 retrotranspositions. Tumors from 53% of patients had at least one such event, with colorectal and lung cancers being most frequently affected (93% and 75% of patients, respectively). Somatic 3′ transductions comprised 24% of events, half of which represented mobilizations of unique sequence alone, without any accompanying L1 sequence. Overall, 95% of 3′ transductions identified derived from only 72 germline L1 source elements, with as few as four loci accounting for 50% of events. In a given sample, the same source element could generate 50 or more somatic transductions, scattered extensively across the genome. About 5% of somatic transductions arose from L1 source elements that were themselves somatic retrotranspositions. In three of the cases in which we sequenced more than one sample from a patient’s tumor, we were able to place 3′ transductions on the phylogenetic tree. We found that the activity of individual source elements fluctuated during tumor evolution, with different subclones exhibiting much variability in which elements were “on” and which were “off.” The ability to identify the individual L1 source elements active in a given tumor enabled us to study the promoter methylation of those elements specifically. We found that 3′ transduction activity in a patient’s tumor was always associated with hypomethylation of that element. Overall, 2.3% of transductions distributed exons or entire genes to other sites in the genome, and many more mobilized deoxyribonuclease I (DNAse-I) hypersensitive sites or transcription factor binding sites identified by the ENCODE project. Occasionally, somatic L1 insertions inserted near coding sequence and redistributed these exons elsewhere in the genome. However, we found no general effects of retrotranspositions on transcription levels of genes at the insertion points and no evidence for aberrant RNA species resulting from somatically acquired transposable elements. Indeed, as with germline retrotranspositions, somatic insertions exhibited a strong enrichment in heterochromatic, gene-poor regions of the genome. Conclusion: Somatic 3′ transduction occurs frequently in human tumors, and in some cases transduction events can scatter exons, genes, and regulatory elements widely across the genome. Dissemination of these sequences appears to be due to a small number of highly active L1 elements, whose activity can wax and wane during tumor evolution. The majority of the retrotransposition events are likely to be harmless “passenger” mutations.

1 July 2016 in Kidney International
Verified
Journal Article
Closed access
NCNATALIA CARRILLO-LOPEZ
NATALIA CARRILLO-LOPEZ
SPSara Panizo
Sara Panizo
CMCristina Alonso Montes
Cristina Alonso Montes
PRPablo Román-García
Pablo Román-García
IRIsabel Rodríguez
Isabel Rodríguez
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía

9 June 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PRPablo Roman-Garcia
Pablo Roman-Garcia
Isabel Quiros-GonzalezIsabel Quiros-Gonzalez
Isabel Quiros-Gonzalez
LMLynda Mottram
Lynda Mottram
LLLiesbet Lieben
Liesbet Lieben
KSKunal Sharan
Kunal Sharan
Vijay YadavVijay Yadav
Vijay Yadav
Both maternal and offspring-derived factors contribute to lifelong growth and bone mass accrual, although the specific role of maternal deficiencies in the growth and bone mass of offspring is poorly understood. In the present study, we have shown that vitamin B12 (B12) deficiency in a murine genetic model results in severe postweaning growth retardation and osteoporosis, and the severity and time of onset of this phenotype in the offspring depends on the maternal genotype. Using integrated physiological and metabolomic analysis, we determined that B12 deficiency in the offspring decreases liver taurine production and associates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) axis. Taurine increased GH-dependent IGF1 synthesis in the liver, which subsequently enhanced osteoblast function, and in B12-deficient offspring, oral administration of taurine rescued their growth retardation and osteoporosis phenotypes. These results identify B12 as an essential vitamin that positively regulates postweaning growth and bone formation through taurine synthesis and suggests potential therapies to increase bone mass.

1 January 2010 in Bone
Verified
Journal Article
Closed access
PRPablo Román-García
Pablo Román-García
NCNATALIA CARRILLO-LOPEZ
NATALIA CARRILLO-LOPEZ
JFJosé Fernández-Martín
José Fernández-Martín
MNManuel Naves-Díaz
Manuel Naves-Díaz
MRMaría P Ruiz
María P Ruiz
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía

28 October 2011 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía
PRPablo Roman-Garcia
Pablo Roman-Garcia
KHKeith Hruska
Keith Hruska
Vascular calcification, bone loss and increased fracture risk are age-associated disorders. Several epidemiological studies have suggested a relationship between vascular calcification, impaired bone metabolism and increased mortality. So far, this relationship had been under-estimated as osteoporosis and vascular calcification have been considered non-modifiable disorders of aging. Recent data suggest that this association is not simply an artefact of age, stressing that the co-incidence of vascular calcification with low bone activity and osteoporosis could be biologically linked. During the development of vascular calcification, the transition of vascular smooth muscle cells towards an osteoblast-like phenotype promotes the release of the vesicular structures and mineralization within these structures is promoted by several players, including those related to mineral metabolism, like phosphorus, calcium or parathyroid hormone, which influence either the supersaturation within the structure or the expression of osteogenic factors. However, an intriguing question is whether the presence of vascular calcification impacts bone metabolism, thus demonstrating true crosstalk between these tissues. Evidence is now emerging, suggesting that some inhibitors of the Wnt pathway, such as secreted frizzled Proteins 2 and 4 and Dickkopf related protein-1 (DKK-1), may play a role linking vascular calcification and bone loss. An additional important question to answer, from the patient’s perspective, is whether or not progression of vascular calcification can be prevented or restricted and whether altering this progression we can efficiently impact patients’ outcomes. Much evidence suggests that the control of the chronic kidney disease–mineral and bone disorder components, particularly serum phosphorus, are the main targets to maintain normal bone turnover and protect against vascular calcification.

1 September 2009 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
NCNATALIA CARRILLO-LOPEZ
NATALIA CARRILLO-LOPEZ
PRPablo Román-García
Pablo Román-García
ARAna Rodríguez-Rebollar
Ana Rodríguez-Rebollar
JFJosé Luis Fernández-Martín
José Luis Fernández-Martín
MNManuel Naves-Díaz
Manuel Naves-Díaz
JCJorge B. Cannata-Andía
Jorge B. Cannata-Andía
The mechanisms by which estrogens modulate PTH are controversial, including whether or not estrogen receptors (ERs) are present in the parathyroid glands. To explore these mechanisms, we combined a rat model of CKD with ovariectomy and exogenous administration of estrogens. We found that estrogen treatment significantly decreased PTH mRNA and serum levels. We did not observe ERα or ERβ mRNA or protein in the parathyroids, suggesting an indirect action of estrogens on PTH regulation. Estrogen treatment significantly decreased serum 1,25(OH)2 vitamin D3 and phosphorus levels. In addition, estrogens significantly increased fibroblast growth factor 23 (FGF23) mRNA and serum levels. In vitro, estrogens led to transcriptional and translational upregulation of FGF23 in osteoblast-like cells in a time- and concentration-dependent manner. These results suggest that estrogens regulate PTH indirectly, possibly through FGF23.